Correlation Between Eterna Therapeutics and Allovir

Can any of the company-specific risk be diversified away by investing in both Eterna Therapeutics and Allovir at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eterna Therapeutics and Allovir into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Eterna Therapeutics and Allovir, you can compare the effects of market volatilities on Eterna Therapeutics and Allovir and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eterna Therapeutics with a short position of Allovir. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eterna Therapeutics and Allovir.

Diversification Opportunities for Eterna Therapeutics and Allovir

0.68

Correlation Coefficient

Eterna Therapeutics  Allovir

Poor diversification

The 3 months correlation between Eterna and Allovir is 0.68. Overlapping area represents the amount of risk that can be diversified away by holding Eterna Therapeutics and Allovir in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Allovir and Eterna Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eterna Therapeutics are associated (or correlated) with Allovir. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Allovir has no effect on the direction of Eterna Therapeutics i.e., Eterna Therapeutics and Allovir go up and down completely randomly.

Pair Corralation between Eterna Therapeutics and Allovir

Given the investment horizon of 90 days Eterna Therapeutics is expected to under-perform the Allovir. In addition to that, Eterna Therapeutics is 1.07 times more volatile than Allovir. It trades about -0.28 of its total potential returns per unit of risk. Allovir is currently generating about -0.04 per unit of volatility. If you would invest  75.00  in Allovir on September 12, 2024 and sell it today you would lose (24.00) from holding Allovir or give up 32.0% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Eterna Therapeutics  vs.  Allovir

Eterna Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Eterna Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Allovir

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Allovir has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with Eterna Therapeutics and Allovir

The main advantage of trading using opposite Eterna Therapeutics and Allovir positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eterna Therapeutics position performs unexpectedly, Allovir can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allovir will offset losses from the drop in Allovir's long position.

The idea behind Eterna Therapeutics and Allovir pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.